BRPI0813287A2 - Planejamento e otimização baseados na sequência de anticorpos de cadeia única - Google Patents

Planejamento e otimização baseados na sequência de anticorpos de cadeia única

Info

Publication number
BRPI0813287A2
BRPI0813287A2 BRPI0813287-9A2A BRPI0813287A BRPI0813287A2 BR PI0813287 A2 BRPI0813287 A2 BR PI0813287A2 BR PI0813287 A BRPI0813287 A BR PI0813287A BR PI0813287 A2 BRPI0813287 A2 BR PI0813287A2
Authority
BR
Brazil
Prior art keywords
planning
sequence
single chain
chain antibodies
optimization based
Prior art date
Application number
BRPI0813287-9A2A
Other languages
English (en)
Inventor
Leonardo Borbas
David Urech
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of BRPI0813287A2 publication Critical patent/BRPI0813287A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Evolutionary Biology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
BRPI0813287-9A2A 2007-06-25 2008-06-25 Planejamento e otimização baseados na sequência de anticorpos de cadeia única BRPI0813287A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93711207P 2007-06-25 2007-06-25
US6905708P 2008-03-12 2008-03-12
PCT/CH2008/000284 WO2009000098A2 (en) 2007-06-25 2008-06-25 Sequence based engineering and optimization of single chain antibodies

Publications (1)

Publication Number Publication Date
BRPI0813287A2 true BRPI0813287A2 (pt) 2014-12-30

Family

ID=39855147

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813287-9A2A BRPI0813287A2 (pt) 2007-06-25 2008-06-25 Planejamento e otimização baseados na sequência de anticorpos de cadeia única

Country Status (20)

Country Link
US (1) US9908945B2 (pt)
EP (1) EP2164961B1 (pt)
JP (2) JP5506670B2 (pt)
KR (1) KR101530723B1 (pt)
CN (1) CN101688200B (pt)
AU (1) AU2008267733B2 (pt)
BR (1) BRPI0813287A2 (pt)
CA (1) CA2689064C (pt)
DK (1) DK2164961T3 (pt)
ES (1) ES2532725T3 (pt)
HK (1) HK1137035A1 (pt)
IL (1) IL202352A (pt)
MX (1) MX2009013327A (pt)
NZ (1) NZ581470A (pt)
PL (1) PL2164961T3 (pt)
PT (1) PT2164961E (pt)
RU (1) RU2010102064A (pt)
SI (1) SI2164961T1 (pt)
WO (1) WO2009000098A2 (pt)
ZA (1) ZA200908314B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924597A (zh) * 2005-06-07 2013-02-13 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
KR102007492B1 (ko) 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
DK3241843T3 (da) 2008-06-25 2021-09-06 Novartis Ag Opløselighedsoptimering af immunbindere
PL3216803T3 (pl) 2008-06-25 2020-10-19 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące vegf
HUE039692T2 (hu) 2008-06-25 2019-01-28 Esbatech Alcon Biomed Res Unit TNF-et gátló stabil és oldható ellenanyagok
EP3130603A1 (en) 2008-06-30 2017-02-15 ESBATech, an Alcon Biomedical Research Unit LLC Functionalized polypeptides
KR20110031373A (ko) 2008-07-10 2011-03-25 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 마크로분자 전달을 증강하는 방법 및 조성물
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
BR112012012873B1 (pt) * 2009-12-22 2021-08-31 F.Hoffmann-La Roche Ag Método para fornecer uma sequência de ácido nucleico que codifica uma imunoglobulina e método para produzir uma imunoglobulina
CA2777527C (en) * 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
AU2011279073B2 (en) * 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
JP5704386B2 (ja) * 2010-10-12 2015-04-22 日本電気株式会社 タンパク質分子のアミノ酸置換部位選択装置、置換アミノ酸選択装置、アミノ酸置換部位選択方法、置換アミノ酸選択方法、プログラムおよび記録媒体
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
KR101287625B1 (ko) * 2011-10-10 2013-07-23 대유라디에터공업 주식회사 열교환기용 튜브 제조방법
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
JP6227191B1 (ja) 2014-12-19 2017-11-08 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
GB201502590D0 (en) * 2015-02-16 2015-04-01 Lonza Ag Method and apparatus for designing proteins
CN107002074B (zh) 2015-06-10 2021-08-10 公立大学法人富山县立大学 活性型突变酶的制造方法及活性型突变酶、以及可溶性化突变蛋白的制造方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
CA3240046A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2023220038A1 (en) * 2022-05-10 2023-11-16 Amgen Inc. Machine learning techniques for predicting thermostability
US20240091262A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024122449A1 (ja) * 2022-12-06 2024-06-13 株式会社レボルカ 機械学習による抗体設計法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU6796094A (en) * 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CN1689646A (zh) * 1998-08-11 2005-11-02 拜奥根Idec公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69918717T2 (de) * 1998-12-14 2005-07-21 Osteotech, Inc. Knochentransplantat aus knochenpartikel
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
ATE273323T1 (de) * 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
ATE536375T1 (de) 2000-05-10 2011-12-15 Mayo Foundation Menschliche igm antikörper, welche die fähigkeit besitzen, den wiederaufbau der myelinstruktur zu induzieren und deren diagnostische und therapeutische anwendung im zentralen nervensystem
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
WO2003008451A2 (en) 2001-07-19 2003-01-30 Universität Zürich Modification of human variable domains
AU2003238370B2 (en) 2002-05-22 2010-04-29 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
GB2408508A (en) 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CN102924597A (zh) 2005-06-07 2013-02-13 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
RS57255B1 (sr) 2005-12-13 2018-08-31 Lilly Co Eli Anti-il-17 antitela
SI2046382T1 (sl) * 2006-07-10 2016-12-30 ESBATech an Alcon Biomedical Research Unit LLC Protitelesa scFv, ki prehajajo epitelijske in/ali endotelijske plasti
NZ579594A (en) * 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies

Also Published As

Publication number Publication date
WO2009000098A3 (en) 2009-04-23
CA2689064A1 (en) 2008-12-31
CN101688200A (zh) 2010-03-31
US9908945B2 (en) 2018-03-06
DK2164961T3 (en) 2015-03-02
RU2010102064A (ru) 2011-07-27
MX2009013327A (es) 2010-06-02
ZA200908314B (en) 2011-02-23
PL2164961T3 (pl) 2015-08-31
KR20100028053A (ko) 2010-03-11
SI2164961T1 (sl) 2015-05-29
PT2164961E (pt) 2015-04-08
CA2689064C (en) 2018-04-24
JP2010532324A (ja) 2010-10-07
EP2164961B1 (en) 2015-01-07
ES2532725T3 (es) 2015-03-31
WO2009000098A2 (en) 2008-12-31
US20090028848A1 (en) 2009-01-29
JP5506670B2 (ja) 2014-05-28
NZ581470A (en) 2013-04-26
EP2164961A2 (en) 2010-03-24
IL202352A (en) 2015-06-30
KR101530723B1 (ko) 2015-06-22
AU2008267733B2 (en) 2013-11-14
HK1137035A1 (en) 2010-07-16
CN101688200B (zh) 2012-08-08
IL202352A0 (en) 2011-08-01
JP2014051508A (ja) 2014-03-20
AU2008267733A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
BRPI0813287A2 (pt) Planejamento e otimização baseados na sequência de anticorpos de cadeia única
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
LTPA2016026I1 (lt) Anti-il-17 antikūnai
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
NO344963B1 (no) Humanisert antistoff
ITBO20050495A1 (it) Elettrocatetere esogageo
BRPI0809677A2 (pt) Anticorpos anti-ige
DK2131860T3 (da) Anti-sclerostin-antistoffer
ATE483732T1 (de) Madcam-antikörper
DK3332808T3 (da) Humaniserede L243-antistoffer
NO20071430L (no) Anti-OX4OL antistoffer
DE602005014129D1 (de) Rohrleitung
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DE602006006476D1 (de) Verschluss
BRPI0814003A2 (pt) Formulações de anticorpo
LU92389I2 (fr) Cystéamine
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DE602006021027D1 (de) Verschluss
BRPI0817427A2 (pt) Anticorpo anti-bst2
CR10705A (es) Anticuerpos para linfotoxina-alfa
DE112007003143A5 (de) Kettenverbindungsglied
DE602006020623D1 (de) Fälschungssicherer verschluss
DE602007002602D1 (de) Wirbelverbindungsglied

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements